Melchert PW, Zhang Q, Mukhopadhyay S, Kanumuri SRR, McCurdy CR, Markowitz JS (2023) <br />An in vitro evaluation of kratom (Mitragyna speciosa) on the catalytic activity of carboxylesterase 1 (CES1)<br /><i>Chemico-Biological Interactions</i> <br /><br />Markowitz JS, De Faria L, Zhang Q, Melchert PW, Frye RF, Klee BO, Qian Y (2022) <br />The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects<br /><i>Med Cannabis Cannabinoids</i> <b>5</b>: 199<br /><br />Melchert PW, Qian Y, Zhang Q, Klee BO, Xing C, Markowitz JS (2022) <br />In vitro inhibition of carboxylesterase 1 by Kava (Piper methysticum) Kavalactones<br /><i>Chemico-Biological Interactions</i> <br /><br />Qian Y, Markowitz JS (2022) <br />Prediction of Carboxylesterase 1 (CES1)-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <br /><br />Qian Y, Melchert PW, Markowitz JS (2022) <br />Involvement of esterases in the pulmonary metabolism of beclomethasone dipropionate and the potential influence of cannabis use<br /><i>Chemico-Biological Interactions</i> <br /><br />Zhang Q, Melchert PW, Markowitz JS (2022) <br />In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir<br /><i>Chemico-Biological Interactions</i> <b>365</b>: 110097<br /><br />Shi J, Xiao J, Wang X, Jung SM, Bleske BE, Markowitz JS, Patrick KS, Zhu HJ (2021) <br />Plasma carboxylesterase 1 predicts methylphenidate exposure: a proof-of-concept study using plasma protein biomarker for hepatic drug metabolism<br /><i>Clinical Pharmacology & Therapeutics</i> <br /><br />Qian Y, Markowitz JS (2020) <br />Natural Products as Modulators of CES1 Activity<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>48</b>: 993<br /><br />Qian Y, Gurley BJ, Markowitz JS (2019) <br />The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications<br /><i>J Clin Psychopharmacol</i> <b>39</b>: 462<br /><br />Qian Y, Wang X, Markowitz JS (2019) <br />In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>47</b>: 465<br /><br />Qian Y, Gilliland TK, Markowitz JS (2019) <br />The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin<br /><i>Chemico-Biological Interactions</i> <br /><br />Zhu HJ, Patrick KS, Straughn AB, Reeves OT, 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS (2017) <br />Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers<br /><i>J Clin Psychopharmacol</i> <b>37</b>: 419<br /><br />Zhu HJ, Langaee TY, Gong Y, Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Markowitz JS (2016) <br />CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril<br /><i>European Journal of Clinical Pharmacology</i> <b>72</b>: 681<br /><br />Wang X, Zhu HJ, Markowitz JS (2015) <br />Carboxylesterase 1-Mediated Drug-Drug Interactions between Clopidogrel and Simvastatin<br /><i>Biol Pharm Bull</i> <b>38</b>: 292<br /><br />Kristensen KE, Zhu HJ, Wang X, Gislason GH, Torp-Pedersen C, Rasmussen HB, Markowitz JS, Hansen PR (2014) <br />Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study<br /><i>Clinical Pharmacology & Therapeutics</i> <b>96</b>: 713<br /><br />Markowitz JS, Zhu HJ, Patrick KS (2013) <br />Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability<br /><i>J Child Adolesc Psychopharmacol</i> <b>23</b>: 648<br /><br />Zhu HJ, Markowitz JS (2013) <br />Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation<br /><i>European Journal of Clinical Pharmacology</i> <b>69</b>: 733<br /><br />Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS (2013) <br />Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>344</b>: 665<br /><br />Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JS (2012) <br />Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions<br /><i>Pharm Res</i> <b>29</b>: 972<br /><br />Zhu HJ, Brinda B, Froehlich TE, Markowitz JS (2012) <br />A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants<br /><i>Pharmacogenet Genomics</i> <b>22</b>: 215<br /><br />Zhu HJ, Patrick KS, Markowitz JS (2011) <br />Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: Application to human ethanol interactions<br /><i>Journal of Chromatography B Analyt Technol Biomed Life Sciences</i> <b>879</b>: 783<br /><br />Zhu HJ, Appel DI, Peterson YK, Wang Z, Markowitz JS (2010) <br />Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions<br /><i>Toxicology</i> <b>270</b>: 59<br /><br />Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS (2009) <br />Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril<br /><i>Biochemical Pharmacology</i> <b>77</b>: 1266<br /><br />Zhu HJ, Markowitz JS (2009) <br />Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>37</b>: 264<br /><br />Zhu HJ, Appel DI, Jiang Y, Markowitz JS (2009) <br />Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>37</b>: 1819<br /><br />LeVasseur NL, Zhu HJ, Markowitz JS, DeVane CL, Patrick KS (2008) <br />Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping<br /><i>Journal of Chromatography B Analyt Technol Biomed Life Sciences</i> <b>862</b>: 140<br /><br />Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS (2008) <br />Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis<br /><i>American Journal of Human Genetics</i> <b>82</b>: 1241<br /><br />Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL (2007) <br />Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study<br /><i>Schizophr Res</i> <b>93</b>: 131<br /><br />Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL (2006) <br />Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder<br /><i>Int J Neuropsychopharmacol</i> <b>9</b>: 603<br /><br />Stahl SM, Markowitz JS, Papadopoulos G, Sadik K (2004) <br />Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease<br /><i>Curr Med Res Opin</i> <b>20</b>: 517<br /><br />Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos G (2003) <br />Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine<br /><i>Sleep</i> <b>26</b>: 602<br /><br />Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP, Owens SD, McGurk S, DeVane L, Risch SC (2003) <br />Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study<br /><i>Neurocase</i> <b>9</b>: 274<br /><br />Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G (2003) <br />Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community<br /><i>J Clin Psychiatry</i> <b>64</b>: 466<br /><br />Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J, George MS (2001) <br />A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates<br /><i>Neurocase</i> <b>7</b>: 105<br /><br />